Skip to Content

Posts tagged with "Drug Industry History"

  • Drug Industry History

    Book Review Department

    For those who are interested, I have a review up at Nature Biotechnology of Reasonable Rx: Solving the Drug Price Crisis, a book that proposes an. . .interesting solution for reworking the drug industry. And as Fate would have it, I also have a review in the latest issue of Nature Chemistry of Drug Truths: Read More
  • Cardiovascular Disease

    Farewell to ACAT, and to Lots of Time and Money, Too

    Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had… Read More
  • Biological News

    Genes to Diseases: Hard Work, You Say?

    So I see that the headlines are that it’s proving difficult to relate gene sequences to specific diseases. (Here’s the NEJM, free full-text). I can tell you that the reaction around the drug industry to this news is a weary roll of the eyes and a muttered “Ya don’t say. . .” That’s because we… Read More
  • Drug Industry History

    Who They?

    I try to keep up with the drug-industry news in general, so once in a while I just hop over to Google News and type “pharmaceutical” into the search box. That generally gets me a barrage of press releases, lucky me, and this morning was no different. But what struck me was that basically the… Read More
  • Drug Industry History

    Scientists Running Your Drug Company?

    There’s an interesting article that showed up in the Financial Times about the leadership of drug companies. Specifically, the number of them that are run by scientists (always lower than you would have thought) is dropping even further. “Only one large western pharmaceutical company will be run by a scientist (John Lechleiter of Lilly) Read More
  • Drug Development

    The Mechanical Chemist?

    We use a lot of automated equipment in the drug discovery business. There’s an awful lot of grunt work involved, and in many cases a robot arm is better suited to the task – transferring solutions, especially repetitive transfers of large numbers of samples, is the classic example. High-throughput screening would just not be possible… Read More
  • Drug Industry History

    The Equipment Graveyard

    The comment that showed up recently about unearthing an “original Cable and Wireless dephilostagenator” in a lab reminded me of the huge lab moving job I was in on some years ago. We were packing up the entire company’s research site and moving it to another spot in New Jersey (Bloomfield to Kenilworth), and this… Read More
  • Drug Assays

    Drugs For Bacteria: Really That Hard, Or Not?

    A few readers have told me that I’m being too hard on antibacterial drug discovery, at least on target-based efforts in the field. The other day I asked if anyone could name a single antibacterial drug on the market that had been developed from a target, rather than by screening or modification of existing drugs… Read More
  • Business and Markets

    Roche / Genentech: The Chase Is Over

    So Roche and Genentech have come to terms: $95 per share. They’d offered more last fall, but, well, it isn’t last fall any more. And this was still well above Roche’s recent offers, although they’d come up to $93 in public before this was announced this morning. Genentech shares had been climbing up to much… Read More
  • Business and Markets

    Merck Actually Does It

    So Merck wasn’t kidding about making a large deal, were they? When I used to work for Schering-Plough back in the 1990s, there were constant rumors, the whole eight years I spent there, about the company merging or being taken over. And as far as I know, those have never really ceased – until now… Read More